# Polygonatum polysaccharides as gut microbiota modulators: implications for autophagy-dependent PD-L1 clearance in cancer immunotherapy

## TL;DR

This paper reviews how gut microbiota might transform Polygonatum polysaccharides to influence cancer immunotherapy through autophagy and PD-L1 clearance.

## Contribution

It introduces the novel idea that gut microbiota-mediated metabolism of Polygonatum polysaccharides could enhance cancer immunotherapy via autophagy-dependent PD-L1 degradation.

## Key findings

- Polygonatum polysaccharides are transformed by gut microbiota into bioactive compounds.
- These compounds may influence PD-L1 expression and degradation through autophagy.
- Targeting microbiota metabolism could improve cancer immunotherapy outcomes.

## Abstract

The purpose of this review article is to examine the biotransformation of Polygonatum polysaccharides and the role that gut microbiota plays in that biotransformation. In the past years, PD-L1 has come under much attention as an immune checkpoint target and autophagy-lysosomal mediated degradation of PD-L1 provides new approaches for cancer immunotherapy. This review explores how gut microbiota-mediated biotransformation of Polygonatum polysaccharides may influence PD-L1 expression and degradation, potentially offering a novel approach to enhancing cancer immunotherapy. This synthesis of information highlights the complex relationship between foods, microbiota, and the immune system and supports the emerging idea that targeting microbiota-mediated metabolism and the immune response may be beneficial to improve cancer therapeutics.